Abstract
Background: The treatment of Wilms' tumor has undergone major advances in the past four decades. Current therapy is based on both the stage and pathology of the tumor. We have reviewed our recent experience with this tumor to assess the results of treatment on protocols that generally avoid the use of doxorubicin.
Methods: Between January 1978 and December 1991 we treated 114 children with renal tumors. Ninety-one (80%) had favorable histology Wilms' tumor and 23 (20%), unfavorable histology tumors (13 anaplastic Wilms' tumors, four clear cell tumors of the kidney, and six sarcomatous tumors with rhabdoid elements). Chemotherapy was divided into two eras: 1978–1982 (vincristine and actinomycin-D) and 1983–1991 [vincristine and actinomycin-D for all patients, and cyclophosphamide for those with favorable histology and metastatic disease (n=13) and all patients with anaplastic histology (n=13)]. Four patients with clear cell or rhabdoid/sarcomatous tumor, three of whom are disease-free, were treated with a five-drug regimen (vincristine, doxorubin, cyclophosphamide, platinum, and VP-16). Approximately two thirds of the patients received megavoltage radiotherapy to the tumor bed. Mean abdominal radiation doses from 1978 to 1982 were slightly higher than those used from 1983 to 1991 (2,597±782 cGy vs. 2,039±524 cGy, respectively).
Results: No isolated local failures were observed in any favorable histology patient who received radiotherapy. Among the 91 patients with favorable histology, there was no statistically significant difference in event-free survival irrespective of stage. Outcome for patients with anaplastic or clear cell variants was not different from that for those patients with favorable histology, but there were only small numbers in these groups for comparison. Only children with a rhabdoid/sarcomatous variant demonstrated survival that was different from all others (p=0.00). Our previously reported patients with stage I tumors (<550 g) (n=11) who were treated by nephrectomy only continue to have an excellent outcome (survival 100%).
Conclusions: Wilms' tumors remain highly curable. Some unfavorable histology tumors require intensive therapy. Others such as our stage I tumors may be best observed without adjuvant therapy to avoid the toxicity of treatment.
Similar content being viewed by others
References
Farber S. Chemotherapy in the treatment of Wilms' tumor.JAMA 1966;198:826–36.
Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia.N Engl J Med 1991;324:808–15.
Green DM, Jaffe N, Paed D. The role of chemotherapy in the treatment of Wilms' tumor.Cancer 1979;44:52–7.
Cassady JR, Tefft M, Filler RM, Jaffe N, Paed D, Hellman S. Considerations in the radiation therapy of Wilms' tumor.Cancer 1973;32:598–608.
Breslow NE, Churchill G, Nesmith B, et al. Clinicopathologic features and prognosis for Wilms' tumor patients with metastases at diagnosis.Cancer 1986;58:2501–11.
Wilmas JA, Douglass EC, Lewis S, et al. Reduced therapy for Wilms' tumor: analysis of treatment results from a single institution.J Clin Oncol 1988;6:1630–5.
Macklis RM, Oltikar A, Sallan SE. Wilms' tumor patients with pulmonary metastases.Int J Radiat Oncol Biol Phys 1991;21:1187–93.
Thomas PRM, Tefft M, Compaan PJ, Norkool P, Breslow NE, D'Angio GJ. Results of two radiation therapy randomizations in the third National Wilms' Tumor Study.Cancer 1991;68:1703–7.
Larsen E, Perez-Atayde A, Green DM, Retik A, Clavell LA, Sallan SE. Surgery only for the treatment of patients with stage I (Cassady) Wilms' tumor.Cancer 1990;66:264–6.
D'Angio GJ, Evans AE, Breslow N, et al. The treatment of Wilms' tumor: results of the National Wilms' Tumor Study.Cancer 1976;38:633–46.
Weeks DA, Beckwith JB, Luckey DW. Relapse-associated variables in stage I favorable histology Wilms' tumor: a report of the National Wilms' Tumor Study.Cancer 1987;60:1204–12.
Morgan E, Baum E, Breslow N, Takashima J, D'Angio G. Chemotherapy-related toxicity in infants treated according to the second National Wilms' Tumor Study.J Clin Oncol 1988;6:51–5.
Farewell VT, D'Angio GJ, Breslow N, Norkool P. Retrospective validation of a new staging system for Wilms' tumor.Cancer Clin Trials 1981;4:167–71.
D'Angio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms' tumor: results of the third National Wilms' Tumor Study.Cancer 1989;64:349–60.
Breslow N, Sharples K, Beckwith JB, et al. Prognostic factors in nonmetastatic, favorable histology Wilms' tumor.Cancer 1991;68:2345–53.
Grundy P, Breslow N, Green DM, Sharples K, Evans A, D'Angio GJ. Prognostic factors for children with recurrent Wilms' tumor: results from the second and third National Wilms' Tumor Study.J Clin Oncol 1989;7:638–47.
Green DM, Finklestein JZ, Norkool P, D'Angio GJ. Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine: a report of the National Wilms' Tumor Study.Cancer 1988;62:270–3.
McVeagh P, Ekert H. Hepatotoxicity of chemotherapy following nephrectomy and radiation therapy for right-sided Wilms' tumor.J Pediatr 1975;87:627–8.
Macklis RM, Tarbell NJ. An update of pediatric radiation oncology.Semin Pediatr Surg 1993;2:19–28.
Breslow NE, Palmer NF, Hill LR, Buring J, D'Angio GJ. Wilms' tumor: prognostic factors for patients without metastases at diagnosis: results of the National Wilms' Tumor Study.Cancer 1978;41:1577–89.
Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms' tumor: results from the first National Wilms' Tumor Study.Cancer 1978;41:1937–48.
Sutow WW, Breslow NE, Palmer NF, D'Angio GJ, Takashima J. Prognosis in children with Wilms' tumor metastases prior to or following primary treatment: results from the first National Wilms' Tumor Study (NWTS-1).Am J Clin Oncol 1982;5:339–47.
Breslow N, Churchill G, Beckwith JB, et al. Prognosis for Wilms' tumor patients with nonmetastatic disease at diagnosis—results of the second National Wilms' Tumor Study.J Clin Oncol 1985;3:521–31.
Bonadio JF, Storer B, Norkool P, Farewell VT, Beckwith JB, D'Angio GJ. Anaplastic Wilms' tumor: clinical and pathologic studies.J Clin Oncol 1985;3:513–20.
Zuppan CW, Beckwith JB, Luckey DW. Anaplasia in unilateral Wilms' tumor: a report from the National Wilms' Tumor Study pathology center.Hum Pathol 1988;19:1199–209.
Corey SJ, Andersen JW, Vawter GF, Lack EE, Sallan SE. Improved survival for children with anaplastic Wilms' tumors.Cancer 1991;68:970–4.
Haas JE, Palmer NF, Weinberg AG, Beckwith JB. Ultrastructure of malignant rhabdoid tumor of the kidney: a distinctive renal tumor of children.Hum Pathol 1981;12:646–57.
Haas JE, Bonadio JF, Beckwith JB. Clear cell sarcoma of the kidney with emphasis on ultrastructural studies.Cancer 1984;54:2978–87.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shamberger, R.C., Macklis, R.M. & Sallan, S.E. Recent experience with Wilms' tumor: 1978–1991. Annals of Surgical Oncology 1, 59–65 (1994). https://doi.org/10.1007/BF02303542
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02303542